(MYGN) Myriad Genetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US62855J1043

MYGN: Molecular, Diagnostic, Tests, Oncology, Genetics, Screening, Health

Myriad Genetics, Inc. (NASDAQ:MYGN) is a leader in molecular diagnostic testing and precision medicine, specializing in the development and commercialization of innovative diagnostic products. The company focuses on advancing personalized medicine through its portfolio of genetic tests designed to assess risks for hereditary cancers, guide cancer therapy selection, and provide insights into various health conditions. Myriads offerings include the MyRisk Hereditary Cancer test, which uses DNA sequencing to evaluate genetic cancer risks; BRACAnalysis CDx, a companion diagnostic test for metastatic cancers linked to BRCA variants; and MyChoice CDx, which identifies homologous recombination deficiency in ovarian cancer patients.

The company also provides Prolaris, a prostate cancer prognostic test analyzing RNA expression to determine disease aggressiveness, and EndoPredict, a breast cancer prognostic test using RNA expression to assess tumor biology. Myriads portfolio extends to prenatal and mental health testing, including the Prequel Prenatal Screen for chromosomal disorders, Foresight Carrier Screen for genetic risk assessment, SneakPeek for early gender prediction, and GeneSight for psychotropic medication selection in mental health conditions. Collaborations with Illumina, Memorial Sloan Kettering, MD Anderson, and Flatiron Health underscore its commitment to advancing precision medicine.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics operates at the intersection of genomics and healthcare, aiming to improve patient outcomes through actionable genetic insights. Its diverse product lineup addresses critical areas in oncology, womens health, and pharmacogenomics, positioning it as a key player in the molecular diagnostics industry.

Based on the provided and , Myriad Genetics stock (NASDAQ:MYGN) is currently trading below its 20-, 50-, and 200-day simple moving averages (SMA), indicating bearish momentum. The average true range (ATR) of 0.51 suggests moderate volatility. On a fundamental basis, the companys market cap of $696.82M and price-to-book (P/B) ratio of 0.99 indicate potential undervaluation. However, the negative return on equity (RoE) of -17.36% highlights financial challenges. The forward P/E of 97.09 reflects high expectations for future earnings growth. Overall, MYGN may present a recovery opportunity for long-term investors, but near-term price movements are likely to remain subdued due to technical resistance and profitability concerns.

Additional Sources for MYGN Stock

MYGN Stock Overview

Market Cap in USD 697m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Biotechnology
IPO / Inception 1995-10-05

MYGN Stock Ratings

Growth Rating -66.4
Fundamental -20.7
Dividend Rating 0.08
Rel. Strength -80.8
Analysts 3.33/5
Fair Price Momentum 3.58 USD
Fair Price DCF -

MYGN Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y 0.00%
Payout Consistency 0.3%

MYGN Growth Ratios

Growth Correlation 3m -97.4%
Growth Correlation 12m -85.2%
Growth Correlation 5y -20%
CAGR 5y -24.01%
CAGR/Max DD 5y -0.27
Sharpe Ratio 12m -1.31
Alpha -93.54
Beta 0.957
Volatility 174.83%
Current Volume 7304k
Average Volume 20d 2039.4k
What is the price of MYGN stocks?
As of May 09, 2025, the stock is trading at USD 4.03 with a total of 7,304,023 shares traded.
Over the past week, the price has changed by -43.48%, over one month by -47.87%, over three months by -67.63% and over the past year by -83.17%.
Is Myriad Genetics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Myriad Genetics is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -20.73 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MYGN as of May 2025 is 3.58. This means that MYGN is currently overvalued and has a potential downside of -11.17%.
Is MYGN a buy, sell or hold?
Myriad Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MYGN.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 6
  • Sell: 2
  • Strong Sell: 1
What are the forecast for MYGN stock price target?
According to ValueRays Forecast Model, MYGN Myriad Genetics will be worth about 4 in May 2026. The stock is currently trading at 4.03. This means that the stock has a potential downside of -0.5%.
Issuer Forecast Upside
Wallstreet Target Price 15.3 279.7%
Analysts Target Price 21.2 426.1%
ValueRay Target Price 4 -0.5%